Janssen Pharmaceutica Nv

Ortho-mcneil Pharmaceutical Corp.

Agouron Pharmaceuticals, Inc.

Ortho-mcneil Pharmaceuticlas, Inc.

Janssen Pharmaceuticals, Inc.

Wei Xiao

Richard Apodaca

J Guy Breitenbucher

Chandravadan R Shah

Curt A Dvorak

Jill A Jablonowski

Nicholas I Carruthers

Mark Seierstad

Neelakandha S Mani

Alec D Lebsack

Xiaohu Deng

Jason Christopher Rech

Bryan James Branstetter

Kanaka Pattabiraman

Jing Liu

Chennagiri R Pandit

Dale A Rudolph

Kiev S Ly

James Patrick Edwards

Cheryl A Grice

Barbara A Pio

Jianmei Wei

Henricus Jacobus Maria Gijsen

Wenying Chai

Devin M Swanson

Timothy W Lovenberg

John M Keith

Haripada Khatuya

Natalie Anne Hawryluk

Lars Karlsson

Jeffrey E Merit

Yi Yang

Robin L Thurmond

Alison L Chambers

Annette K Kwok

Siquan Sun

Shao Song Chu

Rohit Kumar Duvadie

Wesley K M Chong

Mirko Zaja

Lin Li

Joan M Pierce

Siguan Sun

Jennifer D Kreisberg

Didier Jean-Calude Berthelot

Barbara Pio

Certain TRPV1-modulating imidazolo-, oxazolo-, and thiazolopyrimdine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.

Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1

Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase

Certain TRPV1-modulating imidazolo-, oxazolo-, and thiazolopyrimdine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease. 

Certain heterocyclic amide compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPA1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease. 

Heterocyclic amides as modulators of TRPA1

Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase

Certain N-heteroarylpiperazinyl urea compounds of Formula (I), as defined in the specification, are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis). 

N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase

Substituted phenylalkynes of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.

Phenylalkynes

Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.

Non-imidazole aryloxyalkylamines

Substituted piperazinyl and diazepanyl benzamides and benzthioamides of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.

Piperazinyl and diazapanyl benzamides and benzthioamides

Substituted phenylalkynes of formula (I) compositions containing them and their methods of use to treat histamine related disorders are described, wherein R, R, R, R, Rand n are as defined.

Substituted phenylpiperidines and phenylpyrrolidines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.

Phenylpiperidines and phenylpyrrolidines

Growing community of inventors

San Diego, CA, United States of America

Wei Xiao